FDA Approval for Moderna’s Flu Vaccine: A Cautionary Tale of Science vs Politics

The US Food and Drug Administration (FDA) recently approved Moderna’s mRNA seasonal flu vaccine, mFlusiva. This approval marks a significant development in immunology, but the journey to this milestone was marred by controversy and a lack of transparency from the FDA.

Influenza remains one of the leading causes of morbidity and mortality worldwide, with up to five million severe cases and 650,000 respiratory deaths annually. The approval of a new vaccine is critical in preventing these outcomes. However, Moderna’s application was initially rejected by the FDA, which claimed that the comparator used in trials did not represent the “best available standard of care” in the US.

Career scientists within the agency were overruled by their director, sparking accusations of a predetermined anti-vaccine agenda. Law professor Richard Hughes IV noted at the time, “It’s all pretext and obfuscation when the real agenda is rejecting conventional science.” This assertion is supported by the fact that the FDA later reversed its decision and agreed to review Moderna’s application after initially telling the company that its selected comparator was acceptable.

The implications of this episode are far-reaching. They suggest a willingness on the part of some within the FDA to compromise scientific integrity for ideological reasons, not a partisan issue but rather a broader problem with the politicization of science in the US. The influence of politics on scientific decision-making can have devastating consequences, as seen in recent years.

The approval of mFlusiva also raises questions about the long-term effects of mRNA vaccines. While these vaccines have been hailed for their high efficacy and adaptability, concerns remain over their potential impact on human health. One study suggests that mRNA vaccines may linger in the body for longer than previously thought, sparking fears about their safety.

Despite these caveats, mFlusiva represents an important step forward in the fight against influenza. Its approval will undoubtedly save countless lives and prevent countless cases of severe illness. However, we must remain vigilant in ensuring that scientific decision-making remains untainted by politics.

The FDA’s approval has also sparked debate about the role of industry-funded research in vaccine development. Moderna’s mRNA technology holds significant promise, but concerns remain over potential conflicts of interest and undue influence on scientific decision-making. As we continue to rely on industry-funded research, it is essential that we maintain rigorous safeguards to prevent these conflicts.

The approval of mFlusiva serves as a reminder of the delicate balance between science and politics. This episode highlights the need for continued vigilance in ensuring that scientific decision-making remains free from ideological influence. By prioritizing evidence-based decision-making and upholding the principles of scientific integrity, we can ensure that scientific progress is not sacrificed at the altar of politics.

mFlusiva will soon be available for adults aged 50 and over, offering a much-needed lifeline in the fight against influenza. As we celebrate this milestone, let us also reflect on the concerning developments that led to its approval. By prioritizing transparency, accountability, and evidence-based decision-making, we can ensure that scientific progress is not compromised by politics.